InFocus Capital Partners, an investment firm specializing in the identification and commercialization of ophthalmic health care innovations, has provided a Series A round of funding for Qura Inc. to advance the QSmart wireless implantable pressure sensor technology and monitoring system.
QSmart will improve medical and surgical management of glaucoma by providing 24/7 monitoring, pressure event detection and real time intraocular pressure updates, according to a company news release. This micro-sized wireless implantable pressure sensor can be programmed to the physician’s exact specifications to monitor and collect the most relevant data concerning IOP changes. The information is then delivered to a handheld device or tablet, allowing physicians to evaluate the effectiveness of current glaucoma treatment for their patients in real-time.
“InFocus Capital Partners is excited to support this breakthrough approach to biomedical pressure measurement and monitoring for glaucoma,” said Robert Rothman, MD, Managing Director. “As ophthalmologists investing in technologies to improve eyecare, it was easy for us to recognize Qura as exactly the type of company we were looking for to help advance and commercialize.”
Dr. Rothman and his founding partner, Ron Weiss, MD, at InFocus are both academically-affiliated and board-certified ophthalmologists.
“What makes this minimally invasive micro-implant and monitoring system so unique is that it will operate autonomously regardless of patient activity,” said Douglas Adams, President and co-founder of Qura. “Glaucoma, a leading cause of vision loss and blindness, is largely undertreated due to poor patient compliance. With QSmart, physicians will now have relevant, targeted data to determine the best treatment plans for the patient and information to help patients achieve increased compliance.”